Diversity in immunogenomics: the value and the challenge
Authors:
Kerui Peng,
Yana Safonova,
Mikhail Shugay,
Alice Popejoy,
Oscar Rodriguez,
Felix Breden,
Petter Brodin,
Amanda M. Burkhardt,
Carlos Bustamante,
Van-Mai Cao-Lormeau,
Martin M. Corcoran,
Darragh Duffy,
Macarena Fuentes Guajardo,
Ricardo Fujita,
Victor Greiff,
Vanessa D. Jonsson,
Xiao Liu,
Lluis Quintana-Murci,
Maura Rossetti,
Jianming Xie,
Gur Yaari,
Wei Zhang,
Malak S. Abedalthagafi,
Khalid O. Adekoya,
Rahaman A. Ahmed
, et al. (10 additional authors not shown)
Abstract:
With the advent of high-throughput sequencing technologies, the fields of immunogenomics and adaptive immune receptor repertoire research are facing both opportunities and challenges. Adaptive immune receptor repertoire sequencing (AIRR-seq) has become an increasingly important tool to characterize T and B cell responses in settings of interest. However, the majority of AIRR-seq studies conducted…
▽ More
With the advent of high-throughput sequencing technologies, the fields of immunogenomics and adaptive immune receptor repertoire research are facing both opportunities and challenges. Adaptive immune receptor repertoire sequencing (AIRR-seq) has become an increasingly important tool to characterize T and B cell responses in settings of interest. However, the majority of AIRR-seq studies conducted so far were performed in individuals of European ancestry, restricting the ability to identify variation in human adaptive immune responses across populations and limiting their applications. As AIRR-seq studies depend on the ability to assign VDJ sequence reads to the correct germline gene segments, efforts to characterize the genomic loci that encode adaptive immune receptor genes in different populations are urgently needed. The availability of comprehensive germline gene databases and further applications of AIRR-seq studies to individuals of non-European ancestry will substantially enhance our understanding of human adaptive immune responses, promote the development of effective diagnostics and treatments, and eventually advance precision medicine.
△ Less
Submitted 1 March, 2021; v1 submitted 20 October, 2020;
originally announced October 2020.
